Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9992-10001

  Harazono, Yosuke ^a   Kho, Dhong Hyo ^a   Balan, Vitaly ^b   Nakajima, Kosei ^a   Zhang, Tianpeng ^a   Hogan, Victor ^a   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Everon Biosciences   (United States)

Author keywords

Apoptosis; Bax; Doxorubicin (DXR); Galectin 3 (Gal 3); Thyroid cancer

Indexed keywords

CARBOHYDRATE; GALECTIN 3; PROTEIN BAX; BAX PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; DIMERIZATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; THYROID CARCINOMA; CELL PROLIFERATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; THYROID TUMOR; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; GALECTIN 3; HUMANS; PROTEIN MULTIMERIZATION; THYROID NEOPLASMS;

EID: 84930461770     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2486     Document Type: Article

References (37)

1. Kondo T, Ezzat S and Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature reviews Cancer. 2006; 6(4):292-306.
2. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
3. Youle RJ and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nature reviews Molecular cell biology. 2008; 9(1):47-59.
4. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG. Cancer drug resistance: an evolving paradigm. Nature reviews Cancer. 2013; 13(10):714-726.
5. Leber B, Geng F, Kale J and Andrews DW. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert reviews in molecular medicine. 2010; 12:e28.
6. Weyhenmeyer B, Murphy AC, Prehn JH and Murphy BM. Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Experimental oncology. 2012; 34(3):192-199.
7. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K and et al. Galectins: a family of animal betagalactoside- binding lectins. Cell. 1994; 76(4):597-598.
8. Yang RY, Rabinovich GA and Liu FT. Galectins: structure, function and therapeutic potential. Expert reviews in molecular medicine. 2008; 10:e17.
9. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR and Wiseman SM. Diagnostic utility of galectin-3 in thyroid cancer. The American journal of pathology. 2010; 176(5):2067-2081.
10. Song L, Tang JW, Owusu L, Sun MZ, Wu J and Zhang J. Galectin-3 in cancer. Clinica chimica acta; international journal of clinical chemistry. 2014; 431C:185-191.
11. Akahani S, Nangia-Makker P, Inohara H, Kim HR and Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer research. 1997; 57(23):5272-5276.
12. Yang RY, Hsu DK and Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(13):6737-6742.
13. Yin XM, Oltvai ZN and Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 1994; 369(6478):321-323.
14. Lin CI, Whang EE, Abramson MA, Donner DB, Bertagnolli MM, Moore FD, Jr. and Ruan DT. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochemical and biophysical research communications. 2009; 379(2):626-631.
15. Bleicken S, Classen M, Padmavathi PV, Ishikawa T, Zeth K, Steinhoff HJ and Bordignon E. Molecular details of Bax activation, oligomerization, and membrane insertion. The Journal of biological chemistry. 2010; 285(9):6636-6647.
16. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B and Anderson KC. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer research. 2005; 65(18):8350-8358.
17. Jackson CL, Dreaden TM, Theobald LK, Tran NM, Beal TL, Eid M, Gao MY, Shirley RB, Stoffel MT, Kumar MV and Mohnen D. Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. Glycobiology. 2007; 17(8):805-819.
18. Demydenko D and Berest I. Expression of galectin-1 in malignant tumors. Experimental oncology. 2009; 31(2):74-79.
19. Fujihara S, Mori H, Kobara H, Rafiq K, Niki T, Hirashima M and Masaki T. Galectin-9 in cancer therapy. Recent patents on endocrine, metabolic & immune drug discovery. 2013; 7(2):130-137.
20. Bao Q, Niess H, Djafarzadeh R, Zhao Y, Schwarz B, Angele MK, Jauch KW, Nelson PJ and Bruns CJ. Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin. Targeted oncology. 2013.
21. De Luca P, Vazquez ES, Moiola CP, Zalazar F, Cotignola J, Gueron G, Gardner K and De Siervi A. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Molecular cancer research: MCR. 2011; 9(8):1078-1090.
22. Yeom SY, Jang HL, Lee SJ, Kim E, Son HJ, Kim BG and Park C. Interaction of testisin with maspin and its impact on invasion and cell death resistance of cervical cancer cells. FEBS letters. 2010; 584(8):1469-1475.
23. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK and Xing M. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. The Journal of clinical endocrinology and metabolism. 2008; 93(8):3106-3116.
24. Wada T and Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004; 23(16):2838-2849.
25. Paron I, Scaloni A, Pines A, Bachi A, Liu FT, Puppin C, Pandolfi M, Ledda L, Di Loreto C, Damante G and Tell G. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochemical and biophysical research communications. 2003; 302(3):545-553.
26. Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, Akahani S, Honjo Y, Yamamoto Y, Raz A and Kubo T. Malignant transformation of thyroid follicular cells by galectin-3. Cancer letters. 2003; 195(1):111-119.
27. Lin HM, Moon BK, Yu F and Kim HR. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis. 2000; 21(11):1941-1945.
28. Wang Y, Nangia-Makker P, Balan V, Hogan V and Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell death & disease. 2010; 1:e101.
29. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Kagawa S and Raz A. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer research. 2003; 63(23):8302-8311.
30. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, Bresalier RS and Raz A. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Molecular and cellular biology. 2004; 24(10):4395-4406.
31. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR and Raz A. Galectin-3 phosphorylation is required for its antiapoptotic function and cell cycle arrest. The Journal of biological chemistry. 2002; 277(9):6852-6857.
32. Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, Shono M, Kanayama HO, Ellerhorst J, Lotan R and Raz A. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer research. 2006; 66(6):3114-3119.
33. Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T and Raz A. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis by activating Akt in human bladder carcinoma cells. Cancer research. 2005; 65(17):7546-7553.
34. Lin CI, Whang EE, Donner DB, Jiang X, Price BD, Carothers AM, Delaine T, Leffler H, Nilsson UJ, Nose V, Moore FD, Jr. and Ruan DT. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Molecular cancer research: MCR. 2009; 7(10):1655-1662.
35. Adams JM and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26(9):1324-1337.
36. Harazono Y, Nakajima K and Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer metastasis reviews. 2013.
37. Ahmad R, Alam M, Rajabi H and Kufe D. The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. The Journal of biological chemistry. 2012; 287(25):20866-20875.